## **Electronic Supporting Information**

# Site-Selective Direct Nitration of 2*H*-Indazoles: Easy Access to 7-Nitroindazoles

Suvam Bhattacharjee and Alakananda Hajra\*a

<sup>a</sup>Department of Chemistry, Visva-Bharati (A Central University), Santiniketan 731235, India

Email: alakananda.hajra@visva-bharati.ac.in

Sl. No.	Topics	Page No.	
1	General information:		
Table S1	Optimization of the reaction conditions:	S3	
2	General experimental procedure for the synthesis of <b>3a-3z</b> :	S4	
3	Structure determination (X-ray crystallographic data for <b>3</b> g):	S4-S6	
4	Large scale synthesis of 7-Nitro-2-( <i>p</i> -tolyl)-2 <i>H</i> -indazole ( <b>3b</b> ):	S6	
5	Experimental procedure for the synthesis of 2-( <i>p</i> -Tolyl)-2 <i>H</i> -indazol- 7-amine (4):	S6-S7	
6	Synthetic procedure of <i>tert</i> -Butyl (2-( <i>p</i> -tolyl)-2 <i>H</i> -indazol-7-yl)carbamate ( <b>5</b> ):	S7	
7	Synthesis of 7-Nitro-2-( <i>p</i> -tolyl)-1-tosyl-1,2-dihydro-3 <i>H</i> -indazol-3- one ( <b>6</b> ):	S7-S8	
8	Synthetic procedure of 2-(4'-Methyl-[1,1'-biphenyl]-3-yl)-7-nitro-2 <i>H</i> - indazole (7):	S8	
9	HRMS analysis of the NO <sub>2</sub> -radical scavenged adduct (8):	S9	
10	Characterization data of the synthesized compounds ( <b>3a</b> –7):	S9-S19	
11	References:	S20	
12	NMR spectra [ $^{1}$ H and $^{13}C{^{1}H}$ ] of synthesized products:	S21-S81	

## Contents

#### **1. General information**:

All reagents were purchased from commercial sources and used without further purification. <sup>1</sup>H NMR spectra were determined on a 400 MHz spectrometer as solutions in CDCl<sub>3</sub>. Chemical shifts are expressed in parts per million ( $\delta$ ) and the signals were reported as s (singlet), d (doublet), t (triplet), m (multiplet), and coupling constants (*J*) were given in Hz. <sup>13</sup>C{<sup>1</sup>H} NMR spectra were recorded at 100 MHz in CDCl<sub>3</sub> solution. Chemical shifts are referenced to CDCl<sub>3</sub> ( $\delta$  = 7.26 for <sup>1</sup>H and  $\delta$  = 77.16 for <sup>13</sup>C{<sup>1</sup>H} NMR) and DMSO-*d*<sub>6</sub> ( $\delta$  = 2.50 for <sup>1</sup>H and  $\delta$  = 39.52 for <sup>13</sup>C{1H} NMR) as internal standard. TLC was done on a silica gel-coated glass slide. All solvents were dried and distilled before use. Commercially available solvents were freshly distilled before the reaction. High-resolution mass spectra (HRMS) were collected using electrospray ionization (ESI) on a time-of-flight (TOF) mass spectrometer. The crystallographic data for the compound **3g** was collected by SCXRD-BRUKER D8QUEST and the crystal data was solved by APEX4 software.

All the 2*H*-indazoles as starting materials were prepared by reported methods.<sup>1,2</sup>

## Table S1. Optimization of the Reaction Conditions<sup>a</sup>



entry	catalyst (40 mol%)	solvent (2 mL)	[NO <sub>2</sub> ]	yield (%)
1	Zn(OTf) <sub>2</sub>	CH <sub>3</sub> CN	Ι	<b>78,</b> 69 <sup>b</sup>
2	Zn(OTf) <sub>2</sub>	Toluene	Ι	18
3	Zn(OTf) <sub>2</sub>	1,2-DCE	Ι	trace
4	Zn(OTf) <sub>2</sub>	MeOH	Ι	nr
5	Zn(OTf) <sub>2</sub>	THF	Ι	nr
6	-	CH <sub>3</sub> CN	Ι	13
7	$Zn(BF_4)_2$	CH <sub>3</sub> CN	Ι	51
8	ZnI <sub>2</sub>	CH <sub>3</sub> CN	Ι	nr
9	Cu(OTf) <sub>2</sub>	CH <sub>3</sub> CN	Ι	56
10	AlCl <sub>3</sub>	CH <sub>3</sub> CN	Ι	61
11	Zn(OTf) <sub>2</sub>	CH <sub>3</sub> CN	II	trace
12	Zn(OTf) <sub>2</sub>	CH <sub>3</sub> CN	III	10
13	Zn(OTf) <sub>2</sub>	CH <sub>3</sub> CN	IV	12
14	Zn(OTf) <sub>2</sub>	CH <sub>3</sub> CN	V	nr
15	-	CH <sub>3</sub> CN	VI	trace
16	Zn(OTf) <sub>2</sub>	CH <sub>3</sub> CN	Ι	52, <sup>c</sup> 66, <sup>d</sup> 75, <sup>e</sup>
17	Zn(OTf) <sub>2</sub>	CH <sub>3</sub> CN	Ι	57, <sup>f</sup> 76, <sup>g</sup> 55, <sup>h</sup> 69 <sup>i</sup>

<sup>*a*</sup>Reaction conditions: All reactions were performed using 0.2 mmol of **1e**, 0.4 mmol of NO<sub>2</sub>-agents and 40 mol% catalysts in 2 mL of solvent for 1 h at 80 °C under N<sub>2</sub> atmosphere. <sup>*b*</sup>Under open atmosphere. <sup>*c*</sup>Using 10 mol% of Zn(OTf)<sub>2</sub>. <sup>*d*</sup>Using 20 mol% of Zn(OTf)<sub>2</sub>. <sup>*e*</sup>Using 1 equiv. of Zn(OTf)<sub>2</sub>. <sup>*f*</sup>Using 1 equiv. of **I**. <sup>*g*</sup>Using 3 equiv. of **I**. <sup>*h*</sup>At 50 °C. <sup>*i*</sup>At 100 °C. nr = no reaction.

## 2. General experimental procedure for the synthesis of 3a-3z:



2*H*-indazoles (**1a-1z**, 0.2 mmol), Fe(NO<sub>3</sub>)<sub>3</sub>.9H<sub>2</sub>O (0.4 mmol, 162 mg), Zn(OTf)<sub>2</sub> (40 mol%, 29 mg) and 2.0 mL CH<sub>3</sub>CN solvent were added to an oven-dried reaction tube, which was equipped with a magnetic stirrer bar. At the last, tube was heated in a preheated oil bath at 80  $^{\circ}$ C under N<sub>2</sub> atmosphere. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction was cooled to room temperature and extracted with ethyl acetate (10-15 mL). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to get the crude residue which was purified by column chromatography on silica gel (60–120 mesh) using a mixture of petroleum ether and ethyl acetate as an eluent to afford their corresponding 7-nitro-2*H*-indazoles (**3a-3z**).

## 3. Structure determination (X-ray crystallographic data for 3g):

The brown block crystal of 3g was obtained by crystallization from a solution in dichloromethane/petroleum ether after purification by column chromatography. The chemical formula of compound 3g: C<sub>14</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub>.





View of ORTEP diagram for the crystal structure of the compound *7-Nitro-2-(m-tolyl)-2H-indazole* (**3g**) (Thermal ellipsoid contour at 50% probability level).

0.71073Å			
$C_{14} H_{11} N_3 O_2$	C <sub>14</sub> H <sub>11</sub> N <sub>3</sub> O <sub>2</sub>		
orthorhombic	orthorhombic		
P 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>			
a = 8.1213(7) Å	$\alpha = 90^{\circ}$		
b = 11.1938(9) Å	$\beta = 90^{\circ}$		
c = 13.6325(11)  Å	γ=90°		
1239.31 Å <sup>3</sup>			
4	4		
3	3		
	$0.71073 \text{ \AA}$ $C_{14} \text{ H}_{11} \text{ N}_3 \text{ O}_2$ orthorhombic $P 2_1 2_1 2_1$ $a = 8.1213(7) \text{ \AA}$ $b = 11.1938(9) \text{ \AA}$ $c = 13.6325(11) \text{ \AA}$ $1239.31 \text{ \AA}^3$ $4$ $3$		

The crystallographic data have been deposited with the Cambridge Crystallographic Data Centre as a supplementary publication with a CCDC reference number CCDC 2313021.



4. Large scale synthesis of 7-Nitro-2-(*p*-tolyl)-2*H*-indazole (3b):

To an oven dried 50 mL round bottom flask equipped with a magnetic bar were charged with 2-(*p*-tolyl)-2*H*-indazole (**1b**, 5.0 mmol, 1.04 g), Fe(NO<sub>3</sub>)<sub>3</sub>.9H<sub>2</sub>O (2 equiv., 4.04 g) and Zn(OTf)<sub>2</sub> (40 mol%, 727 mg) in 20 mL CH<sub>3</sub>CN were added. After that, the round bottom flask was heated in an oil bath at 80 °C for 1 hour under N<sub>2</sub> atmosphere. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction was cooled to room temperature and extracted with 40 mL ethyl acetate. The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to get the crude residue which was purified by column chromatography on silica gel (60–120 mesh) using a mixture of petroleum ether and ethyl acetate (90 : 10) as an eluent to afford the 7-nitro-2-(*p*-tolyl)-2*H*-indazole (**3b**) (64%, 0.80 g) as a yellow solid.

## 5. Experimental procedure for the synthesis of 2-(*p*-Tolyl)-2*H*-indazol-7amine (4):



7-Nitro-2-(*p*-tolyl)-2*H*-indazole (**3b**, 0.1 mmol, 25 mg), Zn powder (15 equiv., 98 mg), Pd(TFA)<sub>2</sub> (40 mol%, 13 mg) and 2 mL EtOH as a solvent were added in an oven dried reaction tube then the tube was heated at 60 °C in an oil bath for 1 h under open atmosphere. Thereafter, the product formation of the reaction was monitored by TLC. After the reaction

was completed, ethanol was evaporated under vacuum using rotary evaporator. The reaction mixture was diluted with ethyl acetate and washed with brine. The organic layer was dried over anhydrous  $Na_2SO_4$ , concentrated and the crude mixture was purified by a flash column chromatography on silica gel (60–120 mesh) using 20% ethyl acetate in hexane on silica gel to afford the corresponding 7-amino-2*H*-indazole (**4**) (16 mg, 73%) as a black gummy mass.

# 6. Synthetic procedure of *tert*-Butyl (2-(*p*-tolyl)-2*H*-indazol-7-yl)carbamate (5):



7-Nitro-2-(*p*-tolyl)-2*H*-indazole (**3b**, 0.1 mmol, 25 mg), (Boc)<sub>2</sub>O (5 equiv., 109 mg), In-metal (5 equiv., 57 mg) and AcOH (10 equiv., 60 mg) in MeOH/ACN (3:1) (2 mL) as solvent were taken in an oven dried reaction tube and stirred at 45 °C for 4 h under open atmosphere. Then the product formation of the reaction was monitored by TLC. After the reaction was completed, the reaction mixture was diluted with ethyl acetate and washed with brine. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated and the crude mixture was purified by a flash column chromatography on silica gel (100–200 mesh) using 3% ethyl acetate in hexane on silica gel to furnish the corresponding 7-amidated derivative **5** (20 mg, 62%) as a light yellow solid.

#### 7. Synthesis of 7-Nitro-2-(p-tolyl)-1-tosyl-1,2-dihydro-3H-indazol-3-one (6):



7-Nitro-2-(*p*-tolyl)-2*H*-indazole (**3b**, 0.1 mmol, 25 mg), 4-methylbenzenesulfinic acid (2 equiv., 31 mg), TBHP (2 equiv., 0.035 mL) in CH<sub>3</sub>CN (2 mL) as a solvent were taken in an

oven dried reaction tube and stirred at room temperature for 8 hr in open atmosphere. Then the product formation of the reaction was monitored by TLC. After the reaction was completed, the reaction mixture was diluted with ethyl acetate and water. The organic layer was dried over anhydrous  $Na_2SO_4$ , concentrated and the crude mixture was purified by a flash column chromatography on silica gel (60–120 mesh) using 18% ethyl acetate in hexane on silica gel to furnish the nitro bearing indazolone derived product **6** (28 mg, 67%) as a brown gummy mass.

# 8. Synthetic procedure of 2-(4'-Methyl-[1,1'-biphenyl]-3-yl)-7-nitro-2*H*-indazole (7):



In an oven-dried reaction tube 2-(3-bromophenyl)-7-nitro-2*H*-indazole (**3i**, 0.1 mmol, 32 mg), *p*-tolylphenylboronic acid (2 equiv., 27 mg), Pd(OAc)<sub>2</sub> (2.0 mol%, 0.4 mg), PPh<sub>3</sub> (4 mol%, 1.0 mg) and Na<sub>2</sub>CO<sub>3</sub> (4.0 equiv., 42.4 mg) were added in 2mL n-propanol:H<sub>2</sub>O (4:1) mixed solvent and stirred at 100 °C under open atmosphere for 1 hr. After the completion of the reaction (monitored by TLC), the crude reaction mixture was extracted with ethyl acetate and brine solution. The organic extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated. The product was subjected to column chromatography (silica gel, 100-200 mesh), eluting with petroleum ether and ethyl acetate (94:6) to afford the product 7 (69%, 23 mg) as a yellow gummy mass.

## 9. HRMS analysis of the NO<sub>2</sub>-radical scavenged adduct (8):



10. Characterization data of the synthesized compounds (3a-7):



7-*Nitro-2-phenyl-2H-indazole (3a):* Green solid (32 mg, 67%); M.p. 174–175 °C;  $R_f = 0.55$  (PE : EA = 85 : 15); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  8.65 (s, 1H), 8.37 (d, J = 7.6 Hz, 1H), 8.11 (d, J = 8.0 Hz, 1H), 7.97 (d, J = 7.6 Hz, 2H), 7.58-7.54 (m, 2H), 7.48-7.45 (m, 1H), 7.22 (d, J = 8.0 Hz, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  141.6, 139.9, 138.1, 129.8, 129.1, 129.0, 126.3, 125.9, 122.8, 121.7, 120.9; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>13</sub>H<sub>10</sub>N<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 240.0768; found: 240.0774.



7-*Nitro-2-(p-tolyl)-2H-indazole (3b):* Yellow solid (38 mg, 75%); M.p. 106–107 °C;  $R_f = 0.5$  (PE : EA = 80 : 20); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  8.59 (s, 1H), 8.32 (d, *J* = 7.6 Hz, 1H), 8.07 (d, *J* = 8.0 Hz, 1H), 7.82 (d, *J* = 8.4 Hz, 2H), 7.31 (d, *J* = 8.4 Hz, 2H), 7.19 (t, *J* = 8.0 Hz, 1H), 2.41 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  141.4, 139.2, 138.0, 137.6, 130.3, 128.9, 126.2, 125.6, 122.6, 121.4, 120.6, 21.2; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>14</sub>H<sub>12</sub>N<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 254.0924; found: 254.0923.



2-(4-(tert-Butyl)phenyl)-7-nitro-2H-indazole (3c): Red gummy mass (37 mg, 63%);  $R_f = 0.5$ (PE : EA = 90 : 10); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  8.61 (s, 1H), 8.35 (d, J = 7.6 Hz, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.89-7.85 (m, 2H), 7.57-7.53 (m, 2H), 7.21 (t, J = 8.0 Hz, 1H), 1.36 (s, 9H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  152.5, 141.5, 138.0, 137.5, 128.9, 126.7, 125.7, 122.7, 121.4, 120.7, 114.4, 34.9, 31.3; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>17</sub>H<sub>18</sub>N<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 296.1394; found: 296.1391.



**2-(4-Fluorophenyl)-7-nitro-2H-indazole (3d):** Yellow solid (36 mg, 71%); M.p. 198–199 °C;  $R_f = 0.45$  (PE : EA = 85 : 15); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.60 (s, 1H), 8.35 (d, J = 7.6 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 7.96-7.92 (m, 2H), 7.25-7.18 (m, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz): δ 162.7 ( $J_{C-F} = 248.0$  Hz), 141.6, 138.0, 136.2, 129.0, 126.3, 126.0, 123.5 ( $J_{C-F} = 9.0$  Hz), 122.9, 121.0, 116.8 ( $J_{C-F} = 23.0$  Hz); HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>13</sub>H<sub>9</sub>FN<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 258.0673; found: 258.0678.



2-(4-Chlorophenyl)-7-nitro-2H-indazole (3e): Yellow solid (43 mg, 78%); M.p. 175-176 °C;  $R_f = 0.55$  (PE : EA = 80 : 20); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  8.62 (s, 1H), 8.36 (d, J = 7.2Hz, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.94-7.91 (m, 2H), 7.53-7.50 (m, 2H), 7.23 (d, J = 7.6 Hz, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  141.7, 138.4, 138.1, 135.0, 130.0, 128.9, 126.3, 126.1, 122.7, 121.2; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>13</sub>H<sub>9</sub><sup>35</sup>ClN<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 274.0378; found: 274.0361.



**2-(4-Bromophenyl)-7-nitro-2H-indazole (3f):** Yellow solid (39 mg, 61%); M.p. 176-177 °C;  $R_f = 0.55$  (PE : EA = 80 : 20); <sup>1</sup>H NMR (DMSO- $d_6$ , 400 MHz):  $\delta$  9.50 (s, 1H), 8.38 (d, J =7.6 Hz, 1H), 8.31 (d, J = 8.4 Hz, 1H), 8.10 (d, J = 8.8 Hz, 2H), 7.83 (d, J = 8.8 Hz, 2H), 7.32 (t, J = 8.0 Hz, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (DMSO- $d_6$ , 400 MHz):  $\delta$  140.6, 138.5, 136.9, 132.7, 130.4, 126.4, 126.0, 124.9, 122.7, 121.6, 121.0; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>13</sub>H<sub>9</sub><sup>81</sup>BrN<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 319.9852; found: 319.9845.



7-*Nitro-2-(m-tolyl)-2H-indazole (3g):* Yellow solid (37 mg, 74%); M.p. 180-181 °C;  $R_f = 0.5$ (PE : EA = 86 : 14); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  8.63 (s, 1H), 8.37-8.35 (m, 1H), 8.11-8.09 (m, 1H), 7.83 (s, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.42 (t, J = 8.0 Hz, 1H), 7.28-7.25 (m, 1H), 7.22 (t, J = 8.0 Hz, 1H) 2.47 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  141.5, 140.1, 139.9, 138.1, 129.9, 129.6, 129.0, 126.2, 125.8, 122.8, 122.4, 120.8, 118.6, 21.5; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>14</sub>H<sub>12</sub>N<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 254.0924; found: 254.0916.



**2-(3-Chlorophenyl)-7-nitro-2H-indazole (3h):** Yellow solid (38 mg, 69%); M.p. 206-207 °C;  $R_f = 0.5$  (PE : EA = 85 : 15); <sup>1</sup>H NMR (DMSO- $d_6$ , 400 MHz): δ 9.46 (s, 1H), 8.35 (d, J = 7.2Hz, 1H), 8.28 (d, J = 8.4 Hz, 1H), 8.18 (t, J = 2.0 Hz, 1H), 8.09-8.07 (m, 1H), 7.63 (t, J = 8.4Hz, 1H), 7.56-7.54 (m, 1H), 7.30 (t, J = 8.0 Hz, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (DMSO- $d_6$ , 100 MHz): δ 140.7, 140.4, 137.0, 134.2, 131.6, 130.5, 128.7, 126.6, 126.0, 125.3, 121.2, 120.7, 119.5; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>13</sub>H<sub>9</sub><sup>35</sup>ClN<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 274.0378; found: 274.0372.



2-(3-Bromophenyl)-7-nitro-2H-indazole (3i): Yellow solid (42 mg, 66%); M.p. 205-206 °C;  $R_f = 0.45$  (PE : EA = 85 : 15); <sup>1</sup>H NMR (DMSO- $d_6$ , 400 MHz):  $\delta$  9.50 (s, 1H), 8.38-8.28 (m, 3H), 8.16-8.13 (m, 1H), 7.71-7.69 (m, 1H), 7.58 (t, J = 8.4 Hz, 1H), 7.31 (t, J = 8.0 Hz, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (DMSO- $d_6$ , 100 MHz):  $\delta$  140.6, 140.5, 136.9, 131.8, 131.6, 130.4, 126.5, 125.9, 125.2, 123.4, 122.4, 121.1, 119.9; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>13</sub>H<sub>9</sub><sup>79</sup>BrN<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 317.9873; found: 317.9871.



**2-(3-Chloro-4-fluorophenyl)-7-nitro-2H-indazole (3j):** Yellow solid (42 mg, 72%); M.p. 219-220 °C;  $R_f = 0.45$  (PE : EA = 85 : 15); <sup>1</sup>H NMR (DMSO- $d_6$ , 400 MHz):  $\delta$  9.44 (s, 1H), 8.37-8.31 (m, 2H), 8.28 (d, J = 8.4 Hz, 1H), 8.14-8.10 (m, 1H), 7.66 (t, J = 9.2 Hz, 1H), 7.31 (t, J = 8.0 Hz, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (DMSO- $d_6$ , 100 MHz):  $\delta$  157.1 ( $J_{C-F} = 247.0$  Hz), 140.6, 136.9, 136.3, 130.5, 126.5, 126.0, 125.4, 123.0, 121.7, 121.2, 120.8 ( $J_{C-F} = 19.0$  Hz), 118.1

 $(J_{C-F} = 23.0 \text{ Hz})$ ; HRMS (ESI-TOF) m/z:  $[M + H]^+$  Calcd for  $[C_{13}H_8^{35}\text{ClFN}_3\text{O}_2]^+$ : 292.0284; found: 292.0299.



*Ethyl 4-(7-nitro-2H-indazol-2-yl)benzoate (3k):* Yellow solid (42 mg, 67%); M.p. 162-163 °C;  $R_f = 0.5$  (PE : EA = 80 : 20); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  8.72 (s, 1H), 8.37-8.35 (m, 1H), 8.22-8.20 (m, 2H), 8.12-8.09 (m, 1H), 8.07 (d, J = 8.4 Hz, 2H), 7.26-7.22 (m, 1H), 4.42 (q, J = 7.2 Hz, 2H), 1.43 (t, J = 7.2 Hz, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  165.6, 142.8, 141.9, 138.2, 131.3, 130.9, 129.1, 126.4, 122.9, 121.3, 121.0, 61.5, 14.4; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>16</sub>H<sub>14</sub>N<sub>3</sub>O<sub>4</sub>]<sup>+</sup>: 312.0979; found: 312.0992.



7-*Nitro-2-(4-(trifluoromethyl)phenyl)-2H-indazole (3l):* Light green solid (38 mg, 62%); M.p. 159-160 °C;  $R_f = 0.55$  (PE : EA = 88 : 12); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  8.72 (s, 1H), 8.37 (d, *J* = 7.6 Hz, 1H), 8.13 (t, *J* = 8.4 Hz, 3H), 7.82 (d, *J* = 8.8 Hz, 2H), 7.26 (t, *J* = 8.0 Hz, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  142.3, 141.9, 138.2, 131.2, 129.1, 127.1 (q, *J*<sub>C-F</sub> = 5 Hz), 126.5, 126.4 (q, *J*<sub>C-F</sub> = 272 Hz), 126.3, 122.9, 121.6, 121.5; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>14</sub>H<sub>9</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 308.0641; found: 308.0644.



7-*Nitro-2-(o-tolyl)-2H-indazole (3m):* Yellow solid (35 mg, 70%); M.p. 227-228 °C;  $R_f = 0.6$ (PE : EA = 85 : 15); <sup>1</sup>H NMR (DMSO- $d_6$ , 400 MHz):  $\delta$  9.06 (s, 1H), 8.40-8.34 (m, 2H), 7.56-7.49 (m, 3H), 7.46-7.44 (m, 1H), 7.34 (t, J = 8.0 Hz, 1H), 2.19 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (DMSO- $d_6$ , 100 MHz):  $\delta$  140.1, 139.5, 136.9, 133.3, 131.4, 130.5, 129.8, 128.8, 126.9, 126.6, 125.8, 125.3, 120.6, 17.5; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>14</sub>H<sub>12</sub>N<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 254.0924; found: 254.0922.



2-(*Naphthalen-1-yl*)-7-*nitro-2H-indazole (3n*): Brown solid (39 mg, 68%); M.p. 234-235 °C;  $R_f = 0.40$  (PE : EA = 85 : 15); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 400 MHz): δ 9.24 (s, 1H), 8.46-8.40 (m, 2H), 8.22 (d, *J* = 8.0 Hz, 1H), 8.13 (d, *J* = 8.4 Hz, 1H), 7.84 (d, *J* = 6.8 Hz, 1H), 7.73 (t, *J* = 8.0 Hz, 1H), 7.67-7.63 (m, 1H), 7.61-7.56 (m, 2H), 7.39 (t, *J* = 8.0 Hz, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (DMSO-*d*<sub>6</sub>, 100 MHz): δ 140.5, 137.0, 136.5, 133.7, 130.7, 130.4, 130.1, 128.3, 128.2, 128.1, 127.2, 126.1, 125.48, 125.45, 124.6, 122.5, 120.8; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>17</sub>H<sub>12</sub>N<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 290.0924; found: 290.0940.



2-(tert-Butyl)-7-nitro-2H-indazole (3o): Yellow gummy mass (28 mg, 63%);  $R_f = 0.55$  (PE : EA = 90 : 10); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  8.30-8.28 (m, 2H), 8.03-8.01 (m, 1H), 7.14 (t, J = 8.0 Hz, 1H), 1.80 (s, 9H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  140.2, 137.8, 128.9, 125.3, 124.7, 121.8, 119.7, 61.6, 30.3; HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for [C<sub>11</sub>H<sub>13</sub>N<sub>3</sub>NaO<sub>2</sub>]<sup>+</sup>: 242.0900; found: 242.0901.



2-Cyclohexyl-7-nitro-2H-indazole (3p): Light orange solid (31 mg, 64%); M.p. 129-130 °C;  $R_f = 0.6$  (PE : EA = 88 : 12); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  8.29 (d, J = 7.6 Hz, 1H), 8.20 (s, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.14 (t, J = 8.0 Hz, 1H), 4.66-4.58 (m, 1H), 2.36-2.33 (m, 2H), 1.96-1.92 (m, 2H), 1.87-1.76 (m, 3H), 1.55-1.43 (m, 2H), 1.36-1.23 (m, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  139.9, 137.5, 128.9, 125.5, 124.9, 122.2, 119.8, 63.6, 34.1, 25.4, 25.2; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>13</sub>H<sub>16</sub>N<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 246.1237; found: 246.1230.



*3-Methyl-7-nitro-2-(p-tolyl)-2H-indazole (3q):* Yellow solid (39 mg, 73%); M.p. 118-119 °C;  $R_f = 0.45$  (PE : EA = 85 : 15); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  8.38 (d, J = 7.2 Hz, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.46 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 7.17 (t, J = 8.0Hz, 1H), 2.68 (s, 3H), 2.45 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  140.5, 139.8, 137.4, 136.6, 135.1, 130.0, 128.9, 126.2, 125.9, 125.5, 119.2, 21.3, 11.4; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>15</sub>H<sub>14</sub>N<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 268.1081; found: 268.1075.



5-Fluoro-7-nitro-2-phenyl-2H-indazole (3r): Yellow solid (36 mg, 70%); M.p. 185-186 °C;  $R_f = 0.5$  (PE : EA = 90 : 10); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.63 (s, 1H), 8.17-8.15 (m, 1H), 7.96-7.94 (m, 2H), 7.75-7.72 (m, 1H), 7.58-7.53 (m, 2H), 7.49-7.45 (m, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz): δ 156.1 ( $J_{C-F} = 242$  Hz), 139.8, 139.0, 138.3, 129.9, 129.3, 125.1 ( $J_{C-F} = 10$  Hz), 122.6 ( $J_{C-F} = 8$  Hz), 121.6, 116.8 ( $J_{C-F} = 32$  Hz), 111.9 ( $J_{C-F} = 24$  Hz); HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>13</sub>H<sub>9</sub>FN<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 258.0673; found: 258.0687.



5-Chloro-7-nitro-2-(p-tolyl)-2H-indazole (3s): Yellow solid (41 mg, 71%); M.p. 201-202 °C;  $R_f = 0.55$  (PE : EA = 90 : 10); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.56 (s, 1H), 8.29 (d, J = 1.6Hz, 1H), 8.05 (d, J = 1.6 Hz, 1H), 7.82 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 2.44 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz): δ 139.9, 139.7, 138.1, 137.4, 130.4, 127.2, 126.4, 126.1, 122.0, 121.4, 21.2; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>14</sub>H<sub>11</sub><sup>35</sup>ClN<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 288.0534; found: 288.0549.



5-Chloro-7-nitro-2-(m-tolyl)-2H-indazole (3t): Yellow solid (37 mg, 65%); M.p. 192-193 °C;  $R_f = 0.55$  (PE : EA = 90 : 10); <sup>1</sup>H NMR (DMSO- $d_6$ , 400 MHz): δ 9.33 (s, 1H), 8.37 (d, J = 1.6 Hz, 1H), 8.25 (d, J = 1.6 Hz, 1H), 7.89 (s, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.48 (t, J = 8.4 Hz, 1H), 7.32 (d, J = 7.6 Hz, 1H), 2.42 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (DMSO- $d_6$ , 100 MHz): δ 139.8, 139.2, 137.4, 130.0, 129.9, 128.8, 126.3, 126.1, 125.1, 124.7, 124.5, 121.5, 118.3, 21.1; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>14</sub>H<sub>11</sub><sup>35</sup>ClN<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 288.0534; found: 288.0536.



5-Chloro-2-(4-chlorophenyl)-7-nitro-2H-indazole (3u): Yellow solid (41 mg, 66%); M.p. 237-238 °C;  $R_f = 0.5$  (PE : EA = 90 : 10); <sup>1</sup>H NMR (DMSO- $d_6$ , 400 MHz): δ 9.41 (s, 1H), 8.41 (d, J = 2.4 Hz, 1H), 8.29 (d, J = 1.2 Hz, 1H), 8.12 (d, J = 8.8 Hz, 2H), 7.68 (d, J = 9.2 Hz, 2H); <sup>13</sup>C{<sup>1</sup>H} NMR (DMSO- $d_6$ , 100 MHz): δ 139.1, 137.9, 137.3, 133.6, 129.9, 128.7, 126.3, 126.2, 124.8, 124.6, 122.6; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>13</sub>H<sub>8</sub><sup>35</sup>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 307.9988; found: 307.9994.



*2-(tert-Butyl)-5-chloro-7-nitro-2H-indazole (3v):* Yellow solid (31 mg, 62%); M.p. 138-139 °C;  $R_f = 0.45$  (PE : EA = 92 : 08); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  8.24 (s, 1H), 8.23 (d, J = 2.0 Hz, 1H), 7.98 (d, J = 1.6 Hz, 1H), 1.79 (s, 9H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  138.7, 137.9, 127.2, 125.5, 125.4, 125.0, 121.3, 62.0, 30.2; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>11</sub>H<sub>13</sub><sup>35</sup>ClN<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 254.0691; found: 254.0691.



6-Chloro-7-nitro-2-(p-tolyl)-2H-indazole (3w): Brown solid (39 mg, 68%); M.p. 146-147 °C;  $R_f = 0.55$  (PE : EA = 88 : 12); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.49 (s, 1H), 7.79 (d, J = 8.8 Hz, 1H), 7.76 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H), 7.14 (d, J = 8.8 Hz, 1H), 2.42 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz): δ 141.9, 139.3, 137.4, 130.4, 125.1, 124.79, 124.72, 123.9, 123.4, 122.2, 121.2, 21.2; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>14</sub>H<sub>11</sub><sup>35</sup>ClN<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 288.0534; found: 288.0531.



6-Methyl-7-nitro-2-(p-tolyl)-2H-indazole (3x): Yellow solid (37 mg, 70%); M.p. 136-137 °C;  $R_f = 0.45$  (PE : EA = 92 : 08); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.43 (s, 1H), 7.76 (d, J = 8.4 Hz, 3H), 7.29 (d, J = 8.4 Hz, 2H), 6.99 (d, J = 8.4 Hz, 1H), 2.58 (s, 3H), 2.41 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz): δ 142.2, 138.8, 138.7, 137.7, 131.7, 130.2, 125.7, 124.5, 123.6, 121.7, 121.1, 21.2, 19.2; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>15</sub>H<sub>14</sub>N<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 268.1081; found: 268.1086.



*1-(4-(7-Nitro-2H-indazol-2-yl)phenyl)ethan-1-one (3y):* Yellow gummy mass (31 mg, 56%);  $R_f = 0.45$  (PE : EA = 70 : 30); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.74 (s, 1H), 8.40-8.38 (m, 1H), 8.17-8.11 (m, 5H), 7.28 (d, J = 7.6 Hz, 1H), 2.68 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz): δ 196.8, 142.9, 142.0, 137.1, 132.6, 130.1, 129.1, 126.5, 126.4, 122.9, 121.5, 121.3, 26.9; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>15</sub>H<sub>12</sub>N<sub>3</sub>O<sub>3</sub>]<sup>+</sup>: 282.0873; found: 282.0867.



*4-(7-Nitro-2H-indazol-2-yl)benzonitrile (3z):* Yellow solid (34 mg, 64%); M.p. 166 -167 °C;  $R_f = 0.5$  (PE : EA = 85 : 25); <sup>1</sup>H NMR (DMSO- $d_6$ , 400 MHz):  $\delta$  9.65 (s, 1H), 8.44-8.34 (m, 4H), 8.15 (d, J = 8.8 Hz, 2H), 7.36 (t, J = 8.0 Hz, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (DMSO- $d_6$ , 100 MHz):  $\delta$  142.3, 140.9, 137.0, 134.2, 130.6, 127.0, 126.1, 125.7, 121.5, 121.4, 118.2, 111.1; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>14</sub>H<sub>9</sub>N<sub>4</sub>O<sub>2</sub>]<sup>+</sup>: 265.0720; found: 265.0706.



2-(*p*-Tolyl)-2*H*-indazol-7-amine (4): Black gummy mass (16 mg, 73%);  $R_f = 0.50$  (PE : EA = 80 : 20); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  8.27 (s, 1H), 7.76 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H), 7.09 (d, J = 8.0 Hz, 1H), 6.95-6.91 (m, 1H), 6.46 (d, J = 7.2 Hz, 1H), 3.62 (s, 2H), 2.42 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  143.1, 138.4, 137.8, 136.9, 130.1, 123.8, 123.4, 120.9, 120.5, 109.4, 105.9, 21.1; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>14</sub>H<sub>14</sub>N<sub>3</sub>]<sup>+</sup>: 224.1182; found: 224.1180.



*tert-Butyl* (2-(*p-tolyl*)-2*H-indazol-7-yl*)*carbamate* (5): Light yellow solid (20 mg, 62%); M.p. 115-116 °C;  $R_f = 0.5$  (PE : EA = 95 : 05); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  8.30 (s, 1H), 7.88-7.86 (m, 1H), 7.76 (d, J = 8.4 Hz, 2H), 7.64 (s, 1H), 7.33-7.29 (m, 3H), 7.07 (t, J = 8.0Hz, 1H), 2.42 (s, 3H), 1.57 (s, 9H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  152.8, 142.6, 138.2, 138.1, 130.2, 128.4, 123.6, 122.9, 120.9, 116.2, 113.5, 111.0, 80.7, 28.5, 21.1; HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for [C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>NaO<sub>2</sub>]<sup>+</sup>: 346.1526; found: 346.1544.



7-*Nitro-2-(p-tolyl)-1-tosyl-1,2-dihydro-3H-indazol-3-one (6):* Brown gummy mass (28 mg, 67%);  $R_f = 0.45$  (PE : EA = 80 : 20); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  8.27 (d, J = 8.0 Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.60 (t, J = 8.0 Hz, 1H), 7.53 (d, J = 8.4 Hz, 2H), 7.25 (d, J = 8.4 Hz, 2H), 7.14 (q, J = 8.8 Hz, 4H), 2.39 (s, 3H), 2.38 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  160.9, 147.1, 141.2, 137.4, 137.1, 133.8, 129.7, 129.5, 129.3, 129.2, 128.9, 128.2, 127.6, 126.6, 122.8, 21.9, 21.2; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>21</sub>H<sub>18</sub>N<sub>3</sub>O<sub>5</sub>S]<sup>+</sup>: 424.0962; found: 424.0951.



2-(4'-Methyl-[1,1'-biphenyl]-3-yl)-7-nitro-2H-indazole (7): Yellow gummy mass (23 mg, 69%);  $R_f = 0.50$  (PE : EA = 80 : 20); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  8.70 (s, 1H), 8.39 (d, J = 7.2 Hz, 1H), 8.16 (t, J = 1.6 Hz, 1H), 8.13 (d, J = 8.0 Hz, 1H), 7.91 (d, J = 7.6 Hz, 1H), 7.68 (d, J = 7.6 Hz, 1H), 7.62 (d, J = 7.6 Hz, 1H), 7.57 (d, J = 8.0 Hz, 2H), 7.31-7.27 (m, 2H), 7.24 (d, J = 8.0 Hz, 1H), 2.42 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  143.2, 141.6, 140.4, 138.2, 136.9, 130.2, 129.8, 129.0, 127.7, 127.2, 126.3, 126.0, 123.0, 121.0, 120.3, 120.2, 21.3; HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for [C<sub>20</sub>H<sub>16</sub>N<sub>3</sub>O<sub>2</sub>]<sup>+</sup>: 330.1237; found: 330.1227.

## 11. References:

- (a) M. R. Kumar, A. Park, N. Park and S. Lee, *Org. Lett.*, 2011, **13**, 3542–3545; (b)
   G. Bogonda, H. Y. Kim and K. Oh, *Org. Lett.*, 2018, **20**, 2711–2715; (c) D. Maiti, K. Mahanty and S. D. Sarkar, *Org. Lett.*, 2021, **23**, 1742–1747.
- 2. S. Bhattacharjee, S. Laru and A. Hajra, Chem. Commun., 2022, 58, 981-984.

12. NMR spectra [<sup>1</sup>H and <sup>13</sup>C{<sup>1</sup>H}] of synthesized products















.





•







2.479 11/11/2 BRUKER Current Data Parameters NAME Dr. A HAJRA 2023 1H 573 1 Me F2 - Acquisition Parameters Date\_ Time INSTRUM PROBHD 20230508 20.12 spect 5 mm PABBO BB/  $NO_2$ PULPROG zg30 3g TD SOLVENT 32768 CDC13 NS DS 8 <sup>1</sup>H NMR:400 MHz SWH 8223.685 Hz FIDRES 0.250967 Hz AQ RG DW DE 1.9922944 sec 1.9922944 sec 186.42 60.800 usec 6.50 usec 299.3 K 1.00000000 sec Solvent: CDCl<sub>3</sub> TE D1 TDO 1 ====== CHANNEL fl ======= 400.1524711 MHz 1H 14.75 usec 12.00000000 W SF01 NUC1 P1 PLW1 F2 - Processing parameters SI 16384 SI SF 400.1500097 MHz WDW EM SSB 0 LB 0.30 Hz GB PC 0 1.00 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm 1.00 0.09 1.00 3.06












•





.













.





.



.



-



۰.













S59













-----






















•

-









